Bullous Pemphigoid Market Expected to reach USD 3.10 Bn by 2032

The bullous pemphigoid market, projected to be valued at USD 1.55 billion in 2025, is set for notable growth, with expectations to reach USD 3.10 billion by 2032, registering a robust CAGR of 10.4% over the forecast period. This expansion is primarily driven by the rising prevalence of autoimmune skin disorders, increasing awareness among healthcare providers, and advancements in diagnostic techniques. Additionally, the growing geriatric population—more prone to developing bullous pemphigoid—combined with ongoing clinical research and the introduction of novel biologic therapies, is further propelling the market growth.

The full report is now available for purchase: https://www.coherentmi.com/industry-reports/bullous-pemphigoid-market 

The bullous pemphigoid market is witnessing steady growth, driven by the rising incidence of autoimmune skin disorders, particularly among the aging population. The disease primarily affects elderly individuals, and with the global geriatric demographic expanding, the demand for effective treatment options is increasing significantly. Advances in immunosuppressive therapies, improved diagnostic tools such as direct immunofluorescence, and the growing use of biologics are further supporting market expansion. The introduction of targeted therapies, including monoclonal antibodies, is transforming the treatment landscape by offering improved efficacy and fewer side effects compared to traditional corticosteroids.

In September 2024, Sanofi and Regeneron announced that the pivotal ADEPT trial of dupilumab in moderate-to-severe bullous pemphigoid met its primary endpoint. Patients treated with dupilumab showed a five-fold higher rate of sustained disease remission compared to placebo, with significant reductions in itch and disease severity.

Regulatory agencies such as the U.S. FDA and the European Medicines Agency (EMA) are promoting faster drug approval pathways for rare diseases through designations like Orphan Drug Status and Breakthrough Therapy. These incentives are accelerating clinical development timelines and encouraging pharmaceutical investment in niche autoimmune dermatological conditions. With continued progress in biologic innovation, personalized medicine approaches, and supportive reimbursement frameworks, the bullous pemphigoid market is poised for substantial growth and therapeutic advancement in the coming years.

There is a growing emphasis on precision medicine in dermatology, with pharmaceutical companies investing in orphan drug development for rare autoimmune conditions like bullous pemphigoid. These efforts aim to personalize treatment strategies by targeting specific immune pathways involved in disease pathogenesis, such as IgE, IL-4, and eotaxin-1 signaling.

For instance, in February 2025, the U.S. Food and Drug Administration (FDA) accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP). The sBLA is supported by data from a pivotal study evaluating the efficacy and safety of Dupixent in 106 adults with moderate-to-severe BP. The primary endpoint was met, with five times more Dupixent patients achieving sustained disease remission compared to those on placebo. Sustained disease remission was defined as complete clinical remission with completion of oral corticosteroids (OCS) taper by week 16 (off OCS treatment and only treated with Dupixent for at least 20 weeks) without relapse and no rescue therapy use during the 36-week treatment period. The study also showed that Dupixent significantly reduced disease severity, itch, and use of OCS compared to placebo.

The market is witnessing increased focus on early and accurate diagnosis through non-invasive and advanced immunopathological tools. Direct and indirect immunofluorescence assays, enzyme-linked immunosorbent assays (ELISA) for BP180 and BP230 antibodies, and newer imaging-based methods are being refined to improve diagnostic accuracy and reduce time to treatment initiation.

A January 2023 study published in the Indian Journal of Dermatology evaluated the enzyme‑linked immunosorbent assay (ELISA) detection of BP180 and BP230 autoantibodies in blister fluid versus serum in 30 untreated BP patients. The BP180 ELISA demonstrated a sensitivity of 95.8% in blister fluid and 88.4% in serum, while BP230 sensitivity was 20% and 16.6% respectively—highlighting blister fluid as a viable, minimally invasive specimen, especially for elderly or difficult‑to‑venipuncture patients.

Bullous pemphigoid predominantly affects elderly individuals, and countries such as China, India, and Brazil are experiencing rapid growth in their geriatric populations. However, diagnosis and treatment rates remain low in many of these regions due to limited awareness and access to specialized dermatological care. This presents a significant opportunity for pharmaceutical companies and diagnostic providers to expand their presence through awareness programs, affordable diagnostics, and localized therapeutic offerings.

Collaborations with regional healthcare systems and dermatology societies could further accelerate early diagnosis and access to novel therapies in these underserved markets.

In July 2024, the Journal of Epidemiology and Global Health, a cross-sectional study, analyzed 1,072 autoimmune bullous disease cases in Shanghai (2016–2023), identifying 434 bullous pemphigoid patients. The data revealed a high proportion of patients from low-income backgrounds and industrial occupations—which typically face limited healthcare access—emphasizing the need for targeted awareness, affordable diagnostics, and regional treatment initiatives.

With the chronic nature of bullous pemphigoid and its recurring flares, there is a growing opportunity to integrate digital health platforms—including mobile apps, teledermatology, and remote monitoring tools—to track symptoms, treatment adherence, and flare progression. These platforms can support patients and caregivers in managing long-term treatment plans while enabling dermatologists to adjust therapies in real time based on remotely collected data.

For example, a hybrid teledermatology cohort study published in the Journal of the American Academy of Dermatology began in late 2023 and continued into September 2024. It included 21 bullous pemphigoid patients managed with an initial in-person visit, followed by monthly teledermatology consultations over 16 weeks. The study reported an 84.8% reduction in BP disease activity (BPDAI-TAS) and a 57% decrease in pruritus after five months, alongside high patient satisfaction scores using the Telemedicine Satisfaction Questionnaire.